A once daily oral RAS(ON) inhibitor met its endpoints in previously treated metastatic pancreatic cancer, landed an ASCO Plenary slot, and was published in The New England Journal of Medicine on the same day.
A once-daily oral RAS(ON) inhibitor met its primary and key secondary endpoints in previously treated metastatic pancreatic cancer, was published in The New England Journal of Medicine, and earned an ASCO Plenary slot. The pricing and access question is real — and the source material does not answer it.
On May 31, 2026, Revolution Medicines announced detailed Phase 3 results for daraxonrasib, a once-daily oral RAS(ON) multi-selective inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The data were presented as a late-breaking abstract (LBA5) at the 2026 ASCO Annual Meeting and published simultaneously in The New England Journal of Medicine — a dual peer-review and plenary combination that is unusual in a disease where second-line options are limited.
RASolute 302 is a randomized Phase 3 trial comparing oral daraxonrasib to standard cytotoxic chemotherapy in patients with previously treated metastatic PDAC. According to the company's May 31 release, the study met all primary and key secondary endpoints, with overall survival and progression-free survival named specifically. STAT News, BioPharma Dive, Pharmaphorum, and Drug Discovery Trends all carried the result on the same day, characterizing it as a rare positive Phase 3 readout in pretreated pancreatic cancer.
The company also reported quality-of-life and pain signals in the same release: delayed deterioration in cancer-related pain and global health status versus chemotherapy, which matters in a disease where symptom burden drives a large share of clinical decision-making.
Daraxonrasib is an oral RAS(ON) multi-selective inhibitor. RAS is the primary oncogenic driver in the majority of PDAC tumors, and the drug is designed to act on tumors with or without a specifically identified RAS mutation. The mechanism is mechanistically distinct from cytotoxic chemotherapy — the comparator arm — and from the limited targeted options currently available in this setting, which is part of why Drug Discovery Trends positioned it as part of a broader wave of non-PD-1 agents reshaping oncology at ASCO 2026.
PDAC is also a disease with a poor survival tail. NCI / PMC cancer statistics anchor the baseline mortality framing: pancreatic cancer remains one of the deadliest common solid tumors, and previously treated metastatic disease has historically had few second-line options with meaningful survival benefit.
A few things are conspicuously absent from the captured source material, and they belong on the record:
The clinical story is real. The simultaneous NEJM publication and ASCO Plenary slot give it peer-review weight that a company press release alone would not. But the access and affordability question that follows from any new PDAC therapy is a separate reporting track, and it is not answered by anything in the source material on hand. That is a gap worth naming, not papering over.